Open AccessPhase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
Author(s) -
Ju Wutong,
Liu Ying,
Wang Lizhen,
Li Jiang,
Ren Guoxing,
Sun Jian,
Tu Wenyong,
Hu Yongjie,
Ji Tong,
Yang Wenjun,
Li Jun,
He Yue,
Wang Yanan,
Zhang Chenping,
Zhong Laiping,
Zhang Zhiyuan
Publication year - 2021
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1002/cac2.12136
Subject(s) - docetaxel , induction chemotherapy , medicine , regimen , chemotherapy , oncology , cisplatin , fluorouracil , clinical endpoint , cancer , randomized controlled trial